MorphoSys Announces #Clinical Milestone from Strategic Alliance

Clinical milestone for MorphoSys AG Clinical milestone for MorphoSys AG: MorphoSys AG announced today that it has received a milestone payment from Novartis in connection with the clinical trial application (CTA/IND) and projected initiation of a phase 1 clinical trial. The HuCAL-derived, fully human antibody will be developed in the therapeutic area of cancer. MorphoSys is currently collaborating on a total of 6 clinical programs with Novartis, 2 in phase 1 and 4 in phase 2.

Have a look at the follow article published by Thomson Reuters here.

Technorati Tags: ,

Leave a Reply

Your email address will not be published. Required fields are marked *